Analyst Andrew Berens of Leerink Partners maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), retaining the price target of $49.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Andrew Berens has given his Buy rating due to a combination of factors, primarily focusing on the strategic developments and potential of Arvinas Holding Company. The company is advancing its pipeline with significant progress in the VERITAC-2 study, which evaluates vepdegestrant monotherapy in treating metastatic breast cancer. The anticipation of upcoming data readouts and the initiation of Phase 3 and Phase 2 trials, particularly those involving combinations with CDK4/6 inhibitors, underpin the confidence in the company’s research direction.
Furthermore, Arvinas’s preparation for commercialization, including building a commercial team, and a strong financial position with cash reserves expected to last into 2027, add to the positive outlook. The ongoing development of the early-stage degrader pipeline, which includes programs targeting LRRK2 and BCL6, further supports the company’s long-term growth potential. These factors collectively contribute to the Buy rating, reflecting optimism about Arvinas’s ability to deliver significant advancements in oncology treatments.
Berens covers the Healthcare sector, focusing on stocks such as AstraZeneca, Exelixis, and Incyte. According to TipRanks, Berens has an average return of -7.0% and a 36.78% success rate on recommended stocks.
In another report released yesterday, BMO Capital also reiterated a Buy rating on the stock with a $82.00 price target.